Bob Azelby, Eliem CEO
Weeks out from an $80M launch, a pain and CNS startup is back with a fresh raise. Can an IPO be far behind?
Not two months after launching out of RA Capital’s incubator, Eliem Therapeutics is returning to the firm — and others — to raise another heap of cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
